Kaimi Biologics Secures Over RMB 100 Million in Pre-A Financing to Accelerate Global Development of Therapeutic Cancer Vaccines
Chimigen
Innovative Immunotherapy Researcher
CASSTAR
Venture Capital Institution
With Views, With Attitude
This is the 1277-4th article from the Life Science Industry Observer WeChat Official Account.
February 18, 2025, Chengdu/Guangzhou, China
Chimigen Bio (Chengdu) Co., Ltd., Focusing on Innovative Therapeutic Vaccine Development(hereinafter referred to as "Chimigen Bio") announced the completion of the first closing of its Pre-A round financing, which was led bySDIC Venture CapitalLead Investment,CASSTARChimigen Bio Completes Over RMB100 Million in Series B+ Financing. This round of financing will be used to accelerate the global clinical trials of its core products SN3001 (a therapeutic vaccine for prostate cancer) and SN2001 (an immunotherapy vaccine for chronic hepatitis B), as well as the ongoing development of therapeutic cancer vaccine products based on the SynNeogen® core technology platform.
Tianfu International Bio City
Dr. Yue Nian Shi, founder of Chimigen Bio, stated:"Chimigen Bio warmly welcomes SDIC Venture Capital Co., Ltd. and CASSTAR as new shareholders. Amid the current capital winter in the industry, the successful first close of Chimigen Bio’s financing round fully demonstrates the capital market's high recognition of our platform technology and the clinical value and commercial prospects of our core pipeline. As an innovation-driven enterprise established during the pandemic and growing amidst the capital winter, we focus on tumor and viral infection immunotherapy, committed to building a differentiated product pipeline with global competitiveness. We extend our heartfelt gratitude to both new and existing shareholders for their strong support at this critical stage of the company’s development. Chimigen Bio will continue to deepen its R&D philosophy of 'innovation-led and science-based,' accelerate the development of multiple therapeutic vaccine products with internationally leading standards and significant clinical value, achieve clinical translation through breakthrough innovations, and contribute social value to the global health cause."
SDIC Venture Capital Co., Ltd. stated
"The dual explosion of regulatory dividends and clinical demand for cancer therapeutic vaccines, coupled with the breakthrough in cold tumor immunotherapy, represents the industry's pinnacle. Chimigen Bio's SynNeogen® platform addresses the fundamental challenge of 'cold tumor immune activation,' offering potential solutions to the two major development hurdles of antigen delivery and immune tolerance in therapeutic vaccines. In line with the mission of 'serving the national innovation strategy and focusing on the transformation of scientific and technological achievements,' as an innovative enterprise in cancer therapeutic vaccines that SDIC Venture Capital Co., Ltd. has strategically invested in, we believe in Chimigen Bio's disruptive potential in the field of cancer vaccines. We are delighted to welcome Chimigen Bio into SDIC Venture Capital's innovation ecosystem, where SDIC Venture Capital will leverage its platform advantages to efficiently integrate industry resources and empower Chimigen Bio's rapid growth."
•
About SDIC Venture Capital
SDIC Venture Capital Co., Ltd. was established in 2016.SDIC GroupSDIC Venture Capital Co., Ltd. is a venture capital fund management company specifically established in a market-oriented manner to implement the national innovation-driven development strategy, deepen the comprehensive strategic cooperation with the Ministry of Science and Technology, and accelerate the transfer and transformation of national scientific and technological achievements. Through platforms such as the National Science and Technology Major Special Achievements Transformation Fund, SDIC Beijing-Tianjin-Hebei Science and Technology Achievement Transformation Fund, SDIC Hi-Tech (Shenzhen) Venture Capital Fund, SDIC (Ningbo) Science and Technology Achievement Transformation Fund, and SDIC (Guangdong) Science and Technology Achievement Transformation Fund, SDIC Venture Capital consistently focuses on the investment goal of transforming scientific and technological achievements. It concentrates on key areas such as advanced manufacturing, electronic information, biomedicine, materials, and energy, while targeting the strategic layout of China’s regional development strategies in Beijing-Tianjin-Hebei, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area. It continuously promotes the independent innovation of key core technologies to achieve breakthroughs and build a sound investment ecosystem for the transformation of scientific and technological achievements.
•
About CASSTAR
CASSTAR is an early-stage investment institution focused on the hard technology sector. As the creator of the "hard technology" concept and a pioneer in "hard technology" investment, CASSTAR is committed to building a hard technology startup ecosystem that integrates "research institutions + early investment + startup platforms + post-investment services," providing tech entrepreneurs with professional, in-depth, and comprehensive investment, incubation, and financing solutions.
•
About Chimigen Bio
Chimigen Bio is a biotechnology company focused on the development of innovative immunotherapies in the two major disease areas of cancer and viral infections. Relying on the world's first SynNeogen® immunotherapy platform technology, the company develops therapies targeting the functions of DC cells to achieve "cold tumor transformation" and functional cures through novel immunotherapy approaches. The company has cumulatively secured nearly 250 million yuan in venture capital investments, attracting investors such as Lapam Capital and SDIC Venture Capital.Puhua Capital(Puhua Capital), CASSTAR, and other top-tier investment institutions. It has successively won honors such as the Sichuan Province Specialized,精细化, and New Small and Medium-sized Enterprise award, and the Disruptive Technology Innovation and Entrepreneurship Competition (Future Health Field) Excellence Award. The company will uphold the R&D ethos of "innovation, breakthrough, and truth-seeking" to bring more and better treatment options to patients worldwide.
---The End---
Welcome to follow the official account by clicking.
If you like it, one-click triple action: like, favorite, and share.！